RVTY · Revvity, Inc.
$88.942026-05-17Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$17
-81.3% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($20 · $5) Analysts Range ($105 · $129) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $3.8B | — | 39.6% | 26.1% | $1.1B | −$3.7B | −$2.6B | 7.7% | — | 9.2% | $12.1B | $8.33 | — |
| 2022.Q4 | $3.3B | -13.5% | 26.7% | 19.8% | $708MM | $35MM | $744MM | 8.7% | — | 5.9% | $12.0B | $5.03 | — |
| 2023.Q4 | $2.8B | -16.9% | 16.4% | 1.9% | $443MM | −$92MM | $351MM | 9.0% | — | 3.9% | $10.8B | $-1.05 | — |
| 2024.Q4 | $2.8B | 0.2% | 16.9% | 10.5% | $416MM | $278MM | $694MM | 8.6% | — | 3.9% | $10.3B | $2.61 | — |
| 2025.Q4 | $2.9B | 3.7% | 14.7% | 9.6% | $381MM | $207MM | $587MM | 9.5% | — | 3.7% | $10.3B | $2.13 | 23.9 |
| italics below = DCF projection · 10yr Rev CAGR: 5% |
| 2026.Q4 | $3.0B | +4.4% | 16.7% | 10.7% | $444MM | −$448MM | −$3MM | 9.3% | −$3MM | 4.2% | $10.8B | $3.07 | 29.0 |
| 2027.Q4 | $3.1B | +5.0% | 17.4% | 11.7% | $480MM | −$530MM | −$50MM | 9.3% | −$42MM | 4.3% | $11.3B | $3.41 | 26.1 |
| 2028.Q4 | $3.3B | +5.4% | 18.0% | 12.7% | $519MM | −$596MM | −$77MM | 9.2% | −$59MM | 4.5% | $11.9B | $3.79 | 23.5 |
| 2029.Q4 | $3.5B | +5.6% | 18.7% | 13.8% | $562MM | −$648MM | −$86MM | 9.1% | −$60MM | 4.6% | $12.6B | $4.21 | 21.1 |
| 2030.Q4 | $3.7B | +5.9% | 20.1% | 14.8% | $630MM | −$710MM | −$79MM | 9.0% | −$51MM | 4.9% | $13.3B | $4.93 | 18.0 |
|
| Term. Yr+ | $4.9B | 4.1% | 20.1% | 20.0% | $780MM | −$372MM | $408MM | 8.6% | $3.8B | 8.6% | — | — | — |
Active scenario IV: $17 (-81.3% vs market)